Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes (T2D) is among the most common and costly disorders worldwide. The goal of current medical management for T2D is to transiently ameliorate hyperglycemia through daily dosing of one or more antidiabetic drugs. Hypoglycemia and weight gain are common side effects of therapy, and sustained disease remission is not obtainable with nonsurgical approaches. On the basis of the potent glucose-lowering response elicited by activation of brain fibroblast growth factor (FGF) receptors, we explored the antidiabetic efficacy of centrally administered FGF1, which, unlike other FGF peptides, activates all FGF receptor subtypes. We report that a single intracerebroventricular injection of FGF1 at a dose one-tenth of that needed for antidiabetic efficacy following peripheral injection induces sustained diabetes remission in both mouse and rat models of T2D. This antidiabetic effect is not secondary to weight loss, does not increase the risk of hypoglycemia, and involves a novel and incompletely understood mechanism for increasing glucose clearance from the bloodstream. We conclude that the brain has an inherent potential to induce diabetes remission and that brain FGF receptors are potential pharmacological targets for achieving this goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
The use of animal models in diabetes research
King, A. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01911.x · Cited by 1,303
Recovery of learning and memory is associated with chromatin remodelling
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007) · Nature · doi:10.1038/nature05772 · Cited by 1,227
Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.-C., Graham, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00348.2009 · Cited by 340
Robins, S. C., Stewart, I., McNay, D. E., Taylor, V., Giachino, C., Goetz, M., Ninkovic, J., Briancon, N., Maratos-Flier, E., Flier, J. S., et al. (2013) · Nature Communications · doi:10.1038/ncomms3049 · Cited by 306
O-Sullivan, I., Zhang, W., Wasserman, D. H., Liew, C. W., Liu, J., Paik, J., DePinho, R. A., Stolz, D. B., Kahn, C. R., Schwartz, M. W., et al. (2015) · Nature Communications · doi:10.1038/ncomms8079 · Cited by 228
Self-citationRyan, K. K., Kohli, R., Gutierrez-Aguilar, R., Gaitonde, S. G., Woods, S. C., & Seeley, R. J. (2013) · Endocrinology · doi:10.1210/en.2012-1891 · Cited by 185
Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo
Titchenell, P. M., Chu, Q., Monks, B. R., & Birnbaum, M. J. (2015) · Nature Communications · doi:10.1038/ncomms8078 · Cited by 169
Ader, M., Pacini, G., Yang, Y. J., & Bergman, R. N. (1985) · Diabetes · doi:10.2337/diab.34.11.1092 · Cited by 169
Self-citationFGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis
Perry, R. J., Lee, S., Ma, L., Zhang, D., Schlessinger, J., & Shulman, G. I. (2015) · Nature Communications · doi:10.1038/ncomms7980 · Cited by 132
Cited by
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
“A single administration of FGF1 peripherally or into the brain produces remarkable sustained remission of experimental diabetes in preclinical studies [26,27], findings postulated to arise in part through increased hepatic glucose uptake [28].”
BackgroundGut-Brain Cross-Talk in Metabolic Control
Clemmensen, C., Müller, T. D., Woods, S. C., Berthoud, H.-R., Seeley, R. J., & Tschöp, M. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.025 · Cited by 297
Diabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Zhu, Q., Chen, X., Xu, X., Zhang, Y., Zhang, C., & Mo, R. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201707371 · Cited by 105
Jin, L., Yang, R., Geng, L., & Xu, A. (2023) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032322-093904 · Cited by 71
Alonge, K. M., Mirzadeh, Z., Scarlett, J. M., Logsdon, A. F., Brown, J. M., Cabrales, E., Chan, C. K., Kaiyala, K. J., Bentsen, M. A., Banks, W. A., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00275-6 · Cited by 63
“Whereas AgRP neurons are confined largely to the ArcM, prominent effects of both diabetes and FGF1 on PNNs were observed in the adjacent ArcL region.”
BackgroundMethodResultSelf-citation
Metadata
- Authors
- Scarlett, J. M., Rojas, J. M., Matsen, M. E., Kaiyala, K. J., Stefanovski, D., Bergman, R. N., Nguyen, H. T., Dorfman, M. D., Lantier, L., Wasserman, D. H., Mirzadeh, Z., Unterman, T. G., Morton, G. J., & Schwartz, M. W.
- Venue
- Nature Medicine
- Published
- 2016-05-23
- Volume
- 22
- Issue
- 7
- Pages
- 800-806
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2396113531
- Cited by
- 151
- References
- 10
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.